"I doubt we will get a partnership in the very short term..."
Keep an open mind wrt the substance of a partnering. Today's CPRX news bodes well for firdapse, but may also bode well for Target Selector utility in a real world setting of CDX. Just a matter of time before we see trial results from the LEMS study incorporating Biocept's platform, and some early indications lend appearance to success all around. Patient stratification for most appropriate treatment might not sound overly glamorous, but it'd set Biocept aside with an LCa niche all it's own.
https://
www.nasdaq.com/article/catalyst-gets-positive-fda-advise-on-firdapse-nda-refiling-cm921500